A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease-Reference-Cited by-同舟云学术

A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

Published:2017-12 Issue:1 Volume:9 Page:
ISSN:1758-9193
Container-title:Alzheimer's Research & Therapy
language:en
Short-container-title:Alz Res Therapy

Author:

Ostrowitzki Susanne, ,Lasser Robert A.,Dorflinger Ernest,Scheltens Philip,Barkhof Frederik,Nikolcheva Tania,Ashford Elizabeth,Retout Sylvie,Hofmann Carsten,Delmar Paul,Klein Gregory,Andjelkovic Mirjana,Dubois Bruno,Boada Mercè,Blennow Kaj,Santarelli Luca,Fontoura Paulo

Funder

F. Hoffmann-La Roche

Publisher

Springer Science and Business Media LLC

Subject

Cognitive Neuroscience,Clinical Neurology,Neurology

Link

http://link.springer.com/content/pdf/10.1186/s13195-017-0318-y.pdf

Reference34 articles.

1. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367(9):795–804.

2. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8(2):101–12.

3. Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet. 2006;368(9533):387–403.